Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- Filing for 1st Japan-Made Nucleic Acid Expected by Year-End If PIII Yields Positive Data
July 1, 2016
- Toho Holdings Appoints Ex-Qol Exec Takada as Senior Executive Officer
July 1, 2016
- Nichi-Iko Aims for 20% Share of Generic Market in “80% Generic Era”: President
June 30, 2016
- Kyowa Kirin’s KRN23 Gets BT Designation for X-Linked Hypophosphatemia in Children
June 30, 2016
- Novel Anti-HIV Agent Genvoya to Hit Japan Market on July 8: JT, Torii
June 30, 2016
- Celgene Files Revlimid for ATL in Japan
June 30, 2016
- Reconsider Appropriate Diabetes Drug Combos Including GLP-1 Agents: Diabetologist
June 29, 2016
- MSD Initiates Long-Term Observational Study of Treatment with Oral Hypoglycemic Agents
June 29, 2016
- Boehringer-Sanofi Asset Swap Slated to Close by Year’s End; Fate of Japan Units Subject to Future Discussions
June 28, 2016
- Daiichi Sankyo, Servier Sign Sales Accord for Edoxaban in Canada
June 28, 2016
- Takeda Returns Japan Rights for Some Amgen Products
June 27, 2016
- Teijin Pharma Will Block Feburic Generic Erosions by Expanding Indications: President
June 24, 2016
- Cellular Dynamics, US National Eye Institute Ink Pact to Advance Cell Transplantation Therapy for AMD
June 24, 2016
- Univ. of Tokyo, Astellas to Codevelop Rice-Based Oral Cholera Vaccine
June 24, 2016
- Sanofi’s Antibody Drug for Atopic Dermatitis Close to Regulatory Filing
June 23, 2016
- Asahi Kasei Inks Collaboration with Finland’s Orion on Pain Therapies
June 23, 2016
- Interview: Bayer Yakuhin Chief Spearheading Initiatives to Trigger Behavior Change in Employees
June 23, 2016
- Fujifilm Inks 1st License Deal for Avigan Patents with Chinese Pharma
June 23, 2016
- Takeda to Partner with US NPO for Joint Program to Explore Lead Compounds for TB Therapies
June 23, 2016
- Bayer Japan Revs Up Drive to Spark Behavior Change, Offers Patient Insights to Back Office Staffers
June 22, 2016
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…